In-Vitro Diagnosis Of Histamine Intolerance Syndrome
Patent No. EP4103946 (titled "In-Vitro Diagnosis Of Histamine Intolerance Syndrome") was filed by Immundiagnostik on Feb 10, 2021. The application was issued on Mar 13, 2024.
Patent Summary
This method diagnoses histamine intolerance syndrome in subjects with suspected insufficient diamine oxidase (DAO) activity. The process involves orally administering a known quantity of stable isotopic labeled histamine, followed by collecting a bodily fluid sample (blood, serum, plasma, urine, or saliva) after a predefined interval. Proteins are optionally removed before chemical derivatization of histamine metabolites using an agent that reacts with imidazole acetic acid and N-methyl-imidazole acetic acid. These derivatized metabolites are measured via LC-MS/MS mass spectrometry. The subject's DAO activity and histamine degradation capacity are then calculated based on the detected amounts of isotopic labeled imidazole acetic acid and methyl imidazole acetic acid.
Patent Family
Patent Oppositions
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents
EP4103946
- Application Number
- EP21705147A
- Filing Date
- Feb 10, 2021
- Status
- Granted And Under Opposition
- Feb 9, 2024
- Publication Date
- Mar 13, 2024
- External Links
- Slate, Register , Google Patents